What's in Novartis Pharmaceuticals's pipeline?

Novartis Pharmaceuticals has 66 drugs in our index: 34 marketed, 0 filed, 3 in Phase 3, 8 in Phase 2, 18 in Phase 1.

Which companies overlap with Novartis Pharmaceuticals's portfolio?

Top competitors by shared drug class: BioNTech, Pfizer, Pfizer Inc., Vaxxinity, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/novartis-pharmaceuticals.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Novartis Pharmaceuticals — Portfolio Competitive Intelligence Brief

Novartis Pharmaceuticals pipeline: 34 marketed, 0 filed, 3 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

34 marketed 0 filed 3 Phase 3 8 Phase 2 18 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Myfortic	Myfortic	marketed			Other
Onasemnogene Abeparvovec-brve	Onasemnogene Abeparvovec-brve	marketed	Gene Therapy	SMN1 gene	Neuroscience
Entresto	Entresto	marketed			Other
Avelox	Avelox	marketed		DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	Infectious Disease
Ofatunumab	Ofatunumab	marketed			Other
Desferasirox	Desferasirox	marketed			Other
Other treatment	Other treatment	marketed	Not specified	Not specified	Other
Tobramycin inhalation powder	Tobramycin inhalation powder	marketed
Anti Thymocyte Globulin	Anti Thymocyte Globulin	marketed	Immunoglobulin G [EPC]
interferon or glatiramer acetate	interferon or glatiramer acetate	marketed
Zolgensma	Zolgensma	marketed			Other
Chelation	Chelation	marketed			Other

Therapeutic area mix

Other · 22
Immunology · 2
Neuroscience · 2
Infectious Disease · 1
Metabolic · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

BioNTech · 1 shared drug class
Pfizer · 1 shared drug class
Pfizer Inc. · 1 shared drug class
Vaxxinity, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Novartis Pharmaceuticals:

Cite this brief

Drug Landscape (2026). Novartis Pharmaceuticals — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/novartis-pharmaceuticals. Accessed 2026-05-16.